Anti-CD16a Antibody, clone 1E6 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 1E6 is a ZooMAb^® rabbit recombinant monoclonal antibody that specifically detects CD16a. It targets an epitope within 25 amino acids from the cytoplasmic domain.

KLH-conjugated linear peptide corresponding to 25 amino acids from the cytoplasmic domain of human CD16a.

Quality Control Testing

Evaluated by Western Blotting in Human spleen tissue lysate.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected CD16a in Human spleen tissue lysate.

Tested Applications

Affinity Binding Assay; A representative lot of this antibody bound CD16a peptide with a KD of 1.0 x 10-12 in an affinity binding assay.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected CD16 in Jurkat cells.

Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected CD16 in Human spleen tissue sections.

Flow Cytometry Analysis: 1 µg from a representative lot detected CD16 in one million Human peripheral blood mononuclear cells (PBMC) co-stained with PE-conjugated CD56.

Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Low Affinity^™ immunoglobulin gamma Fc region receptor III-A (UniProt: P08637; also known as CD16a antigen, Fc-gamma RIII-alpha, Fc-gamma RIII, Fc-gamma RIIIa, FcRIII, FcRIIIa, FcR-10, IgG Fc receptor III-2, CD16a) is encoded by the FCGR3A (also known as CD16A, FCG3, FCGR3, IGFR3) gene (Gene ID: 2214) in human. CD16a is a single-pass type I membrane glycoprotein that is synthesized with a signal peptide (aa 1-16), which is subsequently cleaved off to produce the mature form that contains an extracellular domain (aa 17-208), a transmembrane domain (aa 209-229), and a cytoplasmic domain (aa 230-254). It serves as a receptor for the invariable Fc fragment of immunoglobulin γ. It does not bind free monomeric IgG, thus avoiding inappropriate effector cell activation in the absence of antigenic trigger. It contains high mannose- and complex-type oligosaccharides and its glycosylation at Asn-180 is shown to be essential for high Affinity^™ binding to the Fc and for discrimination between fucosylated and afucosylated IgG glycoforms. It is expressed on natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes, and placental trophoblasts. CD16 serves as a receptor for the Fc region of IgG and binds complexed or aggregated IgG and also monomeric IgG. Phenylalanine 203 in CD16a determines the transmembrane domains and serine 203 in CD16b determines the GPI-anchoring. CD16 is reported to mediate antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis and cytokine production. Mutations in FCGR3A gene have been linked to immunodeficiency 20 that is characterized by functional deficiency of NK cells and makes subjects vulnerable to severe herpes viral infections. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, Affinity^™, reproducibility, and stability over conventional monoclonals. (Ref.: Mao, C., et al. (2021). Antib. Ther. 4(3); 159-170; Ferrara, C., et al. (2011). Proc. Natl. Acad. Sci. USA. 108(31); 12669-12674).

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Affinity is a trademark of Mine Safety Appliances Co.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.